Latest news with #Akums
Fashion Value Chain
08-08-2025
- Business
- Fashion Value Chain
Akums Reports Q1 FY26 with 19% YoY Adj EBITDA Growth; Achieves 1,000 DCGI Approvals
Akums Drugs and Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter ended June 30, 2025. This quarter continued to display strong performance with healthy growth in Adj EBITDA and Adj PAT. In Q1 FY26, Akums reported total income of Rs. 1,051 crore, with healthy Adj EBITDA of Rs. 156 crore reflecting a robust 19.1% year-on-year (YoY) growth. The margins improved to 14.8% from 12.7% last year a 208 bps improvement. During this quarter, the company achieved a key milestone of reaching 1,000 Drug Controller General of India (DCGI) approvals, with 27 fresh approvals in this quarter. The DCGI approvals assist the company in enhancing its product mix, building a differentiated and research-driven portfolio. Additionally, the company also received a patent for its extended-release combination formulation of Doxylamine and Pyridoxine developed using the company's tablet in tablet technology. As part of Akums' strategic vision to establish itself as a leading global CDMO, the company received its first EU dossier approval for Rivaroxaban. It also filed its first dossier of Dapagliflozin combination in Switzerland. Both of these new products hold significant market potential. The commercialization of the EU contract also continues to be on track and the company will commence commercial supplies from April 2027. Akums received 100 mn Euros as part consideration for the EU contract in Q1 this year, consequently the company is at a cash surplus of Rs. 1,518 cr. The strong liquidity position provides a robust foundation for Akums to strategically scale up its business operations through both organic growth initiatives and inorganic opportunities. Segmental Performance Overview Akums' flagship business, CDMO, contributed ~79% to the group turnover with an EBITDA of 14.7% in Q1 FY 26. The company's domestic branded formulation business segment reported ~3% YoY growth while international branded formulation business grew by ~2% YoY. Trade generics and API segment continue to be in operational loss this quarter, though, through the management efforts, the losses are gradually reducing. Commenting on the results, Mr. Sanjeev Jain, Managing Director, said, 'This date marks just over one year since we got listed. We continue to work towards strengthening the organization with a focus on long term growth. Our commitment to becoming a global CDMO player remains steadfast. The recent filings along with the planned global approvals of other facilities are setting up us in that endeavor.' Mr. Sandeep Jain, Managing Director, added, 'We continue to deliver strong performance despite the industry headwinds of decreasing API prices and muted volume growth. With a sustained focus on R&D, we have been able to deliver robust growth. Achieving 1,000 DCGI approvals is a key milestone that stands out Akums from its peers, allowing Akums to offer margin accretive differentiated offerings. We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable and profitable growth in the years ahead.' Extract of Consolidated financial results Particulars (Rs Cr) Q1 FY 26 Q4 FY 25 Q1 FY 25 Revenue 1,024 1,056 1,019 Other income 27 18 7 Total income 1,051 1,073 1,026 Cost of goods sold 582 639 596 Employee Cost 176 184 176 Other Expenses 137 139 123 Adj EBITDA 156 111 131 Adj EBITDA Margin 14.8% 10.4% 12.7% Adj PAT 65 44 57 Adj PAT Margin 6.2% 4.1% 5.6% Definitions Adjusted EBITDA has been calculated as the sum of profit/ (loss) for the quarter, tax expenses, finance costs, depreciation and amortization expense, fair value changes to financial instruments, and exceptional items. Adjusted PAT is calculated as the profit for the quarter plus fair value changes to financial instruments less tax deferred tax created on brought forward losses. CDMO: Contract Development and Manufacturing Operations API: Active Pharmaceutical Ingredients
Mint
10-06-2025
- Business
- Mint
Mid- cap Pharma stock Akum Drugs rebounds 35% from April lows: Should you Buy or Sell the stock?
Stock Market today: The Mid- cap Pharma stock Akum Drugs, has been rebounding well and has risen almost 35% since closing lows in April. Should you Buy or Sell the stock that has seen sharp gains ? Here is what analysts say Akums Drugs and Pharmaceuticals share price has seen sharp gains of almost 35% from closing lows of around ₹ 421 seen on the BSE on 7 April 2025 to ₹ 568 levels now. The Akums Drugs and Pharmaceuticals share price earlier had seen sharp correction, hitting 52 week lows of ₹ 407.40 on 7 April 2025, inline with sharp correction in the markets following global uncertainties and Trump Tariffs ICICI Securities post Q4 FY25 results recently had said that Akums Drugs and Pharmaceuticals' (Akums) Q4FY25 revenue was ahead of our expectation, though unfavorable product mix dented margins. The CDMO business or Contract Development and Manufacturing Business grew a strong 14.8% in Q4 led by volume growth and realisation improvement. They also mentioned that Akums has ₹ 1500 crore in cash on hand, which it may use to expand its export and CDMO operations and add new capabilities. In Q4FY27 supplies for a new 5-year export order for a European client are expected to start. The management expects 8–10% rise in the CDMO, Akumentis, and API segments, with exports expected to grow at a greater rate of 20% in FY26, highlighted ICICI analysts. As per them it also plans to curtail losses in trade generics segment and up to 50% reduction in loss ( ₹ 44 Crore loss in FY25) in API segment in FY26. ICICI Securities maintains BUY ratings, with Sum of the parts or SoTP-based unchanged Target price of ₹ 710. Akums is forming a rounding bottom on the daily charts, having reclaimed its daily moving averages. The recent pullback successfully tested these rising averages, signaling underlying strength. A breakout above ₹ 600 will likely trigger fresh bullish momentum, initially targeting the ₹ 700– ₹ 750 zone. The strong base formation combined with supportive moving averages suggests that the stock is well-positioned for an upside continuation once the breakout level is breached, said Anshul Jain, Head of Research at Lakshmishree Investments Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Fashion Value Chain
27-05-2025
- Business
- Fashion Value Chain
Akums Reports Q4 FY25 with 12.4% Revenue Growth, FY25 Adj. EBITDA Remained Strong at 12.3%
Akums Drugs and Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter and fiscal year ending March 31, 2025. The fourth quarter marked a significant rebound in performance, laying a strong foundation for continued growth and global expansion. In Q4 FY25, Akums reported revenue of Rs.1,073 crore, reflecting a robust 12.4% year-on-year (YoY) growth. The company posted a 10.4% EBITDA margin. Building on its Q4 momentum, Akums closed FY25 with consolidated total income of Rs. 4,170 crore and an adjusted EBITDA margin of 12.3%, a 7-basis point improvement from the previous year. The company continued its focus on enhancing its product mix, building a differentiated, research-driven portfolio, and expanding its global presence. One of the key developments during the fiscal year was securing an approx. €200 million contract for the manufacture and supply of pharmaceutical products to regulated European markets – a milestone that significantly expands Akums' global CDMO footprint. The commercial supplies for this will begin in 2027. To support its expanding footprint, Akums invested Rs. 272 crore in capital expenditure during FY25. which now stands at 49.6 billion units annually. This infrastructure scale-up ensures readiness for large-scale domestic CDMO operations as well as global pharma opportunities. Akums also maintained a strong R&D focus, investing Rs. 130 crore which is over 3% of revenue. With 973 DCGI approvals now, the company's product portfolio has over 4,000 commercialized formulations. This is across multiple therapeutic areas across 60+ dosage forms. Segmental Performance Overview Akums' flagship business, CDMO, contributed ~78% to the group turnover with an adjusted EBITDA of 14.1% in FY 25. The company's domestic branded formulation business segment reported ~9% growth while international branded formulation business grew by ~14%. Trade generics and API segment continue to be in operational loss this fiscal, but the company is taking firm measures to cut the losses in the coming fiscal. Strategic Focus and Future Outlook Despite making meaningful progress across key business segments, Akums reported flat year-on-year revenue, largely due to muted industry volumes and price erosion in APIs. The company, however, continued to invest in long-term growth drivers to consolidate its leadership position in India's pharmaceutical landscape and lay the foundation for global CDMO expansion. With an R&D spend, up 16% from FY24, Akums continues to deepen its innovation capabilities, develop complex formulations, and enrich its portfolio. The company's emphasis on quality-focused manufacturing, novel delivery formats, and patient-centric innovations ensures that its offerings are both globally relevant and therapeutically effective. Commenting on the results, Mr. Sanjeev Jain, Managing Director, said, ' As we look back on the year we got listed, we also look ahead with a renewed sense of purpose. Our entry into Europe is a pivotal step for the Akums' global CDMO expansion. Coupled with strategic capacity expansion and a sharp focus on differentiated offerings, we are laying the foundation for Akums to emerge as a trusted global CDMO. We remain steadfast in our commitment to creating long-term value for all stakeholders and to delivering healthcare solutions that impact lives across geographies.' Mr. Sandeep Jain, Managing Director, added, 'It gives us immense pride to close FY25 on a positive note, especially in a year marked by volatility across the pharmaceutical industry. Despite price erosion in APIs and slowing volumes, Akums remained focused on the fundamentals-operational discipline, innovation, and global ambition. Our new injectable facility is now operational, our R&D engine is stronger than ever, and our differentiated portfolio continues to resonate with partners. These are exciting times, as we accelerate our transformation into a global pharmaceutical manufacturing organization.' Here is the Summary of Profit and Loss Statement for reference P/L (Rs Cr) Q4 FY 25 Q3 FY 25 Q4 FY 24 FY 25 FY 24 Revenue 1,056 1,010 944 4,118 4,178 Other Income 18 15 10 52 34 Total income 1,073 1,025 954 4,170 4,212 COGS 639 602 569 2,433 2,550 Employee Cost 184 176 164 716 647 Other Expenses 139 111 128 508 500 Adj EBITDA 111 136 98 513 515 Adj EBITDA Margin 10.4% 13.3% 10.3% 12.3% 12.2% Depreciation 40 45 34 153 126 Finance Cost 5 5 12 35 51 Exceptional Item -8 -5 0 -17 26 Adj PAT 44 66 46 234 220 Adj PAT Margin 4.1% 6.5% 4.8% 5.6% 5.2%
&w=3840&q=100)
Business Standard
05-05-2025
- Health
- Business Standard
Akums secures patent for dual-action nausea drug for pregnant women
Akums Drugs & Pharmaceuticals has received a patent for its extended-release combination formulation of Doxylamine and Pyridoxine, developed to manage nausea and vomiting in pregnancy (NVP). The formulation, using the company's proprietary 'tablet-in-tablet' technology, has been approved by the Drug Controller General of India (DCGI). NVP affects up to 80 per cent of pregnant women, with around 20 per cent experiencing symptoms throughout their pregnancy. The condition can impact nutrition, daily activity, and overall well-being. Akums' patented formulation combines immediate and sustained drug release in a single tablet, aimed at providing extended symptom relief and reducing dosing frequency. The outer layer of the tablet is designed for rapid onset, while the inner core provides a longer therapeutic effect. This dual-action mechanism is intended to improve dosing convenience and adherence. Commenting on the approval, Sanjeev Jain, Managing Director, Akums, said: 'This new formulation for managing nausea and vomiting during pregnancy ensures access to safe and effective care during a critical phase of life. With this, we are making life a little easier for expectant mothers and helping healthcare move closer to where it should be — accessible, reliable, and full of care.' The formulation has undergone a bioequivalence study. While subject numbers remain confidential as per regulatory norms, the data submitted was deemed sufficient for DCGI approval. Akums says the combination is positioned to address a treatment gap in pregnancy care by offering longer-lasting symptom control. Akums is a contract development and manufacturing organisation (CDMO) with 12 manufacturing units, four R&D centres, and more than 16,000 employees. It reports over 4,100 commercialised formulations and 220 products under development. The company's product pipeline spans multiple dosage forms and therapeutic categories. This development adds to Akums' existing portfolio of drug delivery innovations aimed at both domestic and export pharmaceutical markets.
